Difference between revisions of "Raloxifene (Evista)"
m |
Warner-admin (talk | contribs) |
||
| Line 18: | Line 18: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
Revision as of 22:44, 28 February 2020
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Raloxifene has estrogen antagonist properties in uterine and breast tissues. However, it has estrogen agonist properties in bone, helping to decrease bone resorption.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Raloxifene (Evista) patient drug information (Chemocare)[3]
- Raloxifene (Evista) patient drug information (UpToDate)[4]
Also known as
- Brand names: Evista, Ralista, Razylan